<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00084695</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000365544</org_study_id>
    <secondary_id>PSCI-2003-232</secondary_id>
    <nct_id>NCT00084695</nct_id>
  </id_info>
  <brief_title>Umbilical Cord Blood for Stem Cell Transplantation in Treating Young Patients With Malignant or Nonmalignant Diseases</brief_title>
  <official_title>The Use Of Umbilical Cord Blood As A Source Of Hematopoietic Stem Cells</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Milton S. Hershey Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Umbilical cord blood transplantation may be able to replace immune cells that were&#xD;
      destroyed by chemotherapy or radiation therapy.&#xD;
&#xD;
      PURPOSE: This phase II trial is studying how well umbilical cord blood works as a source of&#xD;
      stem cells in treating patients with types of cancer as well as other diseases.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Determine the impact of the use of umbilical cord blood as a source of hematopoietic&#xD;
           stem cells for children with life-threatening oncologic, hematologic, or&#xD;
           genetic/metabolic disorders in need of a stem cell transplant.&#xD;
&#xD;
        -  Compare the incidence of graft-versus-host disease in patients receiving cord blood&#xD;
           transplants in this study with historical data for unrelated donor stem cell&#xD;
           transplants.&#xD;
&#xD;
        -  Compare the incidence of engraftment in patients receiving cord blood transplants in&#xD;
           this study with historical data for unrelated donor stem cell transplants.&#xD;
&#xD;
      OUTLINE:&#xD;
&#xD;
        -  Preparative therapy: Patients are treated on 1 of 4 preparative therapy regimens.&#xD;
&#xD;
             -  Regimen A: Patients undergo total body irradiation (TBI) two times daily on days -7&#xD;
                to -4. Patients receive cyclophosphamide IV over 30-60 minutes on days -3 and -2&#xD;
                and anti-thymocyte globulin (ATG) IV over at least 6 hours on days -3 to -1.&#xD;
&#xD;
             -  Regimen B (patients who do not receive TBI): Patients receive oral busulfan 4 times&#xD;
                daily on days -8 to -5, and ATG IV over at least 6 hours and melphalan IV over&#xD;
                15-20 minutes on days -4 to -2.&#xD;
&#xD;
             -  Regimen C (patients with Fanconi's anemia and related disorders): Patients undergo&#xD;
                TBI on day -6. Patients receive ATG IV over at least 6 hours and methylprednisolone&#xD;
                IV on days -5 to -1 and fludarabine IV over 30 minutes and cyclophosphamide IV over&#xD;
                30-60 minutes on days -5 to -2.&#xD;
&#xD;
             -  Regimen D: Patients receive oral or IV busulfan 4 times daily on days -9 to -5, ATG&#xD;
                IV over at least 6 hours on days -5 to -3, and cyclophosphamide IV over 30-60&#xD;
                minutes on days -5 to -2.&#xD;
&#xD;
        -  Cord blood transplant: All patients undergo umbilical cord blood transplantation on day&#xD;
           0.&#xD;
&#xD;
        -  Graft-versus-host disease prophylaxis: Patients receive oral or IV cyclosporine twice&#xD;
           daily beginning on day -1. Patients also receive methylprednisolone IV twice daily&#xD;
           beginning on day 5 and continuing until at least day 28.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 25 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>September 2003</start_date>
  <primary_completion_date type="Anticipated">December 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Impact of the use of umbilical cord blood as a source of hematopoietic stem cells</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Comparison of the incidence of graft-vs-host disease with historical data</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Comparison of the incidence of engraftment with historical data</measure>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">25</enrollment>
  <condition>Childhood Langerhans Cell Histiocytosis</condition>
  <condition>Fanconi Anemia</condition>
  <condition>Leukemia</condition>
  <condition>Lymphoma</condition>
  <condition>Myelodysplastic Syndromes</condition>
  <condition>Neuroblastoma</condition>
  <condition>Sarcoma</condition>
  <condition>Unspecified Childhood Solid Tumor, Protocol Specific</condition>
  <arm_group>
    <arm_group_label>Regimen A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients undergo total body irradiation (TBI) two times daily on days -7 to -4. Patients receive cyclophosphamide IV over 30-60 minutes on days -3 and -2 and anti-thymocyte globulin (ATG) IV over at least 6 hours on days -3 to -1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Regimen B (patients who do not receive TBI)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive oral busulfan 4 times daily on days -8 to -5, and ATG IV over at least 6 hours and melphalan IV over 15-20 minutes on days -4 to -2.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Regimen C (patients with Fanconi's anemia/related disorders)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients undergo TBI on day -6. Patients receive ATG IV over at least 6 hours and methylprednisolone IV on days -5 to -1 and fludarabine IV over 30 minutes and cyclophosphamide IV over 30-60 minutes on days -5 to -2.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Regimen D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive oral or IV busulfan 4 times daily on days -9 to -5, ATG IV over at least 6 hours on days -5 to -3, and cyclophosphamide IV over 30-60 minutes on days -5 to -2.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>anti-thymocyte globulin</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Regimen A</arm_group_label>
    <arm_group_label>Regimen B (patients who do not receive TBI)</arm_group_label>
    <arm_group_label>Regimen C (patients with Fanconi's anemia/related disorders)</arm_group_label>
    <arm_group_label>Regimen D</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>busulfan</intervention_name>
    <description>Given orally</description>
    <arm_group_label>Regimen B (patients who do not receive TBI)</arm_group_label>
    <arm_group_label>Regimen D</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclophosphamide</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Regimen A</arm_group_label>
    <arm_group_label>Regimen C (patients with Fanconi's anemia/related disorders)</arm_group_label>
    <arm_group_label>Regimen D</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fludarabine phosphate</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Regimen C (patients with Fanconi's anemia/related disorders)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>melphalan</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Regimen B (patients who do not receive TBI)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>methylprednisolone</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Regimen C (patients with Fanconi's anemia/related disorders)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiation therapy</intervention_name>
    <description>Patients undergo radiation therapy two times daily on days -7 to -4.</description>
    <arm_group_label>Regimen A</arm_group_label>
    <arm_group_label>Regimen C (patients with Fanconi's anemia/related disorders)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Diagnosis of malignant or non-malignant disease, including but not limited to any of&#xD;
             the following:&#xD;
&#xD;
               -  Acute myeloid leukemia or acute lymphoblastic leukemia (ALL) with resistant&#xD;
                  disease beyond first clinical remission (CR)&#xD;
&#xD;
               -  ALL in first CR at high-risk because of 1 of the following factors:&#xD;
&#xD;
                    -  Hypoploidy&#xD;
&#xD;
                    -  Pseudodiploidy with translocations t(9;22), t(4;11), or t(8;14)&#xD;
&#xD;
                    -  Elevated WBC at diagnosis as follows:&#xD;
&#xD;
                         -  &gt; 100,000/mm^3 for patients 6-12 months of age&#xD;
&#xD;
                         -  &gt; 50,000/mm^3 for patients 10-20 years of age&#xD;
&#xD;
                         -  &gt; 20,000/mm^3 for patients 21 years of age&#xD;
&#xD;
                    -  Burkitt's lymphoma/leukemia&#xD;
&#xD;
               -  Chronic myelogenous leukemia in first chronic phase or beyond&#xD;
&#xD;
               -  Juvenile myelomonocytic leukemia&#xD;
&#xD;
               -  Advanced stage or relapsed lymphoma&#xD;
&#xD;
               -  Advanced stage or relapsed solid tumors, including any of the following:&#xD;
&#xD;
                    -  Neuroblastoma&#xD;
&#xD;
                    -  Ewing's sarcoma&#xD;
&#xD;
                    -  Rhabdomyosarcoma&#xD;
&#xD;
               -  Myelodysplastic syndromes, excluding patients with grade 3 or 4 myelofibrosis&#xD;
&#xD;
               -  Familial erythrophagocytic histiocytosis&#xD;
&#xD;
               -  Histiocytosis unresponsive to medical management&#xD;
&#xD;
               -  Inborn errors of metabolism&#xD;
&#xD;
               -  Langerhans cell histiocytosis unresponsive to medical management&#xD;
&#xD;
               -  Immune deficiencies, including:&#xD;
&#xD;
                    -  Severe combined immune deficiency&#xD;
&#xD;
                    -  Wiskott-Aldrich&#xD;
&#xD;
               -  Hemoglobinopathies, including sickle cell disease and thalassemia&#xD;
&#xD;
               -  Severe aplastic anemia&#xD;
&#xD;
               -  Fanconi's anemia&#xD;
&#xD;
               -  Metabolic storage diseases&#xD;
&#xD;
          -  Unrelated cord blood donor must be HLA-identical OR may be mismatched for 1, 2, or 3&#xD;
             HLA-loci (A, B, DR)&#xD;
&#xD;
          -  No other existing HLA-identical related donor available at the time of transplantation&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  21 and under&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  Not specified&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>21 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kenneth G. Lucas, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Milton S. Hershey Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Penn State Hershey Cancer Institute at Milton S. Hershey Medical Center</name>
      <address>
        <city>Hershey</city>
        <state>Pennsylvania</state>
        <zip>17033-0850</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kenneth G. Lucas, MD</last_name>
      <phone>717-531-6012</phone>
      <email>klucas@psu.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2008</verification_date>
  <study_first_submitted>June 10, 2004</study_first_submitted>
  <study_first_submitted_qc>June 10, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 11, 2004</study_first_posted>
  <last_update_submitted>January 9, 2014</last_update_submitted>
  <last_update_submitted_qc>January 9, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 10, 2014</last_update_posted>
  <responsible_party>
    <name_title>Kenneth Gerald Lucas</name_title>
    <organization>Penn State Children's Hospital</organization>
  </responsible_party>
  <keyword>childhood myelodysplastic syndromes</keyword>
  <keyword>recurrent childhood rhabdomyosarcoma</keyword>
  <keyword>unspecified childhood solid tumor, protocol specific</keyword>
  <keyword>previously treated childhood rhabdomyosarcoma</keyword>
  <keyword>previously untreated childhood rhabdomyosarcoma</keyword>
  <keyword>disseminated neuroblastoma</keyword>
  <keyword>regional neuroblastoma</keyword>
  <keyword>recurrent neuroblastoma</keyword>
  <keyword>metastatic Ewing sarcoma/peripheral primitive neuroectodermal tumor</keyword>
  <keyword>recurrent Ewing sarcoma/peripheral primitive neuroectodermal tumor</keyword>
  <keyword>recurrent childhood acute lymphoblastic leukemia</keyword>
  <keyword>juvenile myelomonocytic leukemia</keyword>
  <keyword>childhood acute lymphoblastic leukemia in remission</keyword>
  <keyword>childhood Burkitt lymphoma</keyword>
  <keyword>recurrent childhood lymphoblastic lymphoma</keyword>
  <keyword>stage III childhood lymphoblastic lymphoma</keyword>
  <keyword>stage IV childhood lymphoblastic lymphoma</keyword>
  <keyword>recurrent childhood small noncleaved cell lymphoma</keyword>
  <keyword>stage III childhood small noncleaved cell lymphoma</keyword>
  <keyword>stage IV childhood small noncleaved cell lymphoma</keyword>
  <keyword>recurrent childhood large cell lymphoma</keyword>
  <keyword>stage III childhood large cell lymphoma</keyword>
  <keyword>stage IV childhood large cell lymphoma</keyword>
  <keyword>stage III childhood Hodgkin lymphoma</keyword>
  <keyword>stage IV childhood Hodgkin lymphoma</keyword>
  <keyword>previously treated myelodysplastic syndromes</keyword>
  <keyword>Fanconi anemia</keyword>
  <keyword>de novo myelodysplastic syndromes</keyword>
  <keyword>secondary myelodysplastic syndromes</keyword>
  <keyword>childhood chronic myelogenous leukemia</keyword>
  <keyword>chronic phase chronic myelogenous leukemia</keyword>
  <keyword>relapsing chronic myelogenous leukemia</keyword>
  <keyword>childhood Langerhans cell histiocytosis</keyword>
  <keyword>recurrent childhood acute myeloid leukemia</keyword>
  <keyword>recurrent/refractory childhood Hodgkin lymphoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Sarcoma</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Neuroblastoma</mesh_term>
    <mesh_term>Histiocytosis, Langerhans-Cell</mesh_term>
    <mesh_term>Fanconi Syndrome</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Fanconi Anemia</mesh_term>
    <mesh_term>Histiocytosis</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methylprednisolone</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Melphalan</mesh_term>
    <mesh_term>Busulfan</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Fludarabine phosphate</mesh_term>
    <mesh_term>Antilymphocyte Serum</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

